{"entity": "publication", "iuid": "322314b2ecc94d8a871afeaa786aee16", "timestamp": "2026-08-20T20:52:57.481Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/322314b2ecc94d8a871afeaa786aee16.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/322314b2ecc94d8a871afeaa786aee16"}}, "title": "PDGFR\u00df targeted positron emission tomography as a non-invasive biomarker for activated hepatic stellate cells: lasts steps before clinical translation.", "authors": [{"family": "Yashaswini", "given": "Chittampalli N", "initials": "CN"}, {"family": "Mitran", "given": "Bogdan", "initials": "B"}, {"family": "Papadopoulos", "given": "Natalia", "initials": "N"}, {"family": "Wegrzyniak", "given": "Olivia", "initials": "O"}, {"family": "L\u00f6fblom", "given": "John", "initials": "J"}, {"family": "Nordstr\u00f6m", "given": "Helena", "initials": "H"}, {"family": "Velikyan", "given": "Irina", "initials": "I"}, {"family": "Abouzayed", "given": "Ayman", "initials": "A"}, {"family": "Johansson", "given": "Lars", "initials": "L"}, {"family": "Hagmar", "given": "Per", "initials": "P"}, {"family": "Wagner", "given": "Michael", "initials": "M"}, {"family": "Frejd", "given": "Fredrik Y", "initials": "FY"}, {"family": "Korsgren", "given": "Olle", "initials": "O"}, {"family": "Heldin", "given": "Carl-Henrik", "initials": "CH"}, {"family": "Friedman", "given": "Scott L", "initials": "SL"}, {"family": "Eriksson", "given": "Olof", "initials": "O", "orcid": "0000-0002-2515-8790", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/85991bf00e4b4a26ab15599d25c58601.json"}}], "type": "journal article", "published": "2025-12-13", "journal": {"title": "EJNMMI Radiopharm Chem", "issn": "2365-421X", "volume": "10", "issue": "1", "pages": "80", "issn-l": null}, "abstract": "BACKGROUND: Activated hepatic stellate cells (aHSCs) are the key cell population in the injured liver driving fibrogenesis. aHSCs express platelet-derived growth factor receptor beta (PDGFR\u00df), which is absent from quiescent HSCs. PDGFR\u00df is therefore an attractive target of PET tracers for imaging of fibrogenesis. Here, we present the pharmacological characterization of [68Ga]Ga-DOTA-Cys-ATH001 in preparation for clinical translation and further confirm PDGFR\u00df as a biomarker of activated HSCs in liver disease by single cell sequencing. METHODS: The expression of PDGFR\u00df in subpopulations of HSCs was evaluated in scRNAseq datasets from both a mouse and human liver samples. DOTA-Cys-ATH001 was evaluated for affinity and mechanism of binding to PDGFR\u00df. [68Ga]Ga-DOTA-Cys-ATH001 was evaluated for binding in vitro in mouse and human liver biopsies. The in vivo stability, biodistribution, pharmacokinetics, dosimetry and microdosing toxicology were evaluated in rats and pigs. RESULTS: PDGFR\u00df expression was specifically upregulated in activated HSCs. [68Ga]Ga-DOTA-Cys-ATH001 could differentiate fibrotic liver from healthy liver. The binding co-localized with tissue areas positive for collagen deposition and PDGFR\u00df immunostaining. Based on the microdosing toxicology study the no observed adverse effect level was at least 1000 \u00b5g/kg, suggesting that the intended clinical PET scan dose is safe for use. Dosimetry calculations of [68Ga]Ga-DOTA-Cys-ATH001 predicted an effective dose in human amenable to repeated examinations. CONCLUSIONS: The data presented here suggests that PDGFR\u03b2 PET imaging with [68Ga]Ga-DOTA-Cys-ATH001 has potential for non-invasive detection of activated HSCs. Clinical translation of [68Ga]Ga-DOTA-Cys-ATH001 is ongoing.", "doi": "10.1186/s41181-025-00410-2", "pmid": "41389114", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12711615"}, {"db": "pii", "key": "10.1186/s41181-025-00410-2"}], "notes": [], "created": "2026-08-20T12:37:23.285Z", "modified": "2026-08-20T12:37:23.377Z"}